{
    "clinical_study": {
        "@rank": "11611", 
        "acronym": "WoundWand", 
        "arm_group": [
            {
                "arm_group_label": "WoundWand\u2122 Debridement Device", 
                "arm_group_type": "Active Comparator", 
                "description": "Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound"
            }, 
            {
                "arm_group_label": "Standard of Care sharp debridement", 
                "arm_group_type": "Active Comparator", 
                "description": "Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound"
            }
        ], 
        "brief_summary": {
            "textblock": "A Pilot Study of the WoundWand\u2122 Debridement Device on Infection Prevention"
        }, 
        "brief_title": "A Pilot Study of the WoundWand\u2122 Debridement Device on Infection Prevention", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic and Acute Wounds, Diabetic Foot Ulcers and Venous Leg Ulcers Below the Knee", 
        "condition_browse": {
            "mesh_term": [
                "Leg Ulcer", 
                "Ulcer", 
                "Varicose Ulcer", 
                "Foot Ulcer", 
                "Diabetic Foot"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary aim of this pilot study is to investigate differences in bacterial content of\n      the study wound that may impact upon infection rates following debridement with the\n      WoundWand Debridement Device or Standard of Care (SoC) surgical (sharp) debridement.\n      Additionally, the clinical investigation will evaluate reduction in wound size\n      post-debridement and gather Health Economic data relating to wound bed debridement with the\n      WoundWand Debridement Device or SoC."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Subjects who meet the following criteria may be included in the clinical investigation, if\n        they present with ALL of the following:\n\n          1. Subject is able to understand the evaluation and willing to consent and comply with\n             all post-debridement visits and procedures\n\n          2. Age 18 years and older. Subjects may be of either sex and of any race or skin type\n\n          3. Subjects fulfilling any one or all of the following criteria:\n\n               1. chronic wound(s) below the level of the knee, defined by delayed healing or\n                  cellular senescence\n\n               2. acute wound(s) as a result of a surgical procedure, laceration, abrasion or\n                  trauma\n\n               3. diabetic foot ulcer(s)\n\n               4. subjects with venous leg ulcers below the knee on the leg or foot with one or\n                  more documented failure of maximal medical therapy for their study wound >30\n                  days such as compression bandages (low elasticity, elastic, multilayered,\n                  elastic and non elastic compression)\n\n          4. Subjects with the following lab results within 30 days of treatment:\n\n               1. serum albumin level >20g/L\n\n               2. clinically non significant results of  liver function test (LFTs), serum glucose\n                  and complete blood count (CBC) with differential\n\n          5. Subjects with a Braden Score \u226513-14 (Moderate Risk)\n\n          6. Subjects with adequate arterial blood flow [Ankle-Brachial Index (ABI) >0.75]\n\n        Exclusion Criteria\n\n        Subjects will be excluded from the clinical investigation, if they present with ANY of the\n        following:\n\n          1. Subjects that have tunneling wounds\n\n          2. Subject presents with an active infection in the study wound, as defined by purulence\n             and:\n\n               1. Fever and leukocytosis\n\n                  OR any TWO of the following:\n\n               2. Malodor, pain or tenderness, warmth, erythema, induration, swelling,\n                  lymphangitis\n\n          3. Infected bone diagnosed by imaging modality (e.g., Magnetic Resonance Imaging (MRI)\n             and/or radiographic images)\n\n          4. Subjects whose study wound does not require debridement\n\n          5. Cardiac pacemaker or other electronic implant(s)\n\n          6. Subjects with irradiate, burn or ischaemic wounds or history of keloids\n\n          7. Subjects with vasculitis, non-reconstructive peripheral vascular disease, pyoderma\n             gangrenosum, renal failure or lymphoedema\n\n          8. Subjects with uncontrolled bleeding disorder (PT/PTT) and coagulopathy (including\n             those with hemophilia)\n\n          9. Subjects taking treatment with any of the following:\n\n               1. Systemic corticosteroids\n\n               2. Immunosuppressive agent(s)\n\n               3. Chemotherapy or Radiation therapy\n\n         10. Subjects deemed to require biologic dressing/ skin substitute\n\n         11. Terminally ill subjects\n\n         12. Subjects that have an immunodeficiency disorder that interferes with wound healing,\n             including Acquired Immunodeficiency Syndrome (AIDS) or know to be infected with Human\n             Immunodeficiency Virus (HIV)\n\n         13. Subjects that have chronic skin conditions such as psoriasis, etc.\n\n         14. Subjects that reside in a nursing home\n\n         15. Subject is physically or mentally compromised (e.g., currently being treated for a\n             psychiatric disorder, senile dementia, Alzheimer's disease, etc.) to the extent that\n             the Investigator judges the subject to be unable or unlikely to remain compliant\n\n         16. Subject is pregnant and/or intending to become pregnant during this clinical\n             investigation period\n\n         17. Subject has documented evidence of a history (e.g. liver testing) of drug/alcohol\n             abuse within the 12 months prior to enrollment for clinical investigation entry\n\n         18. Subject is excluded if they have received an investigational therapy or approved\n             therapy for investigational use within 30 days of surgery\n\n         19. Subject is excluded if planning to participate in another research study during the\n             follow-up phase of this study or 84 days after study completion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01924806", 
            "org_study_id": "WW-2013-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "WoundWand\u2122 Debridement Device", 
                "description": "Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound", 
                "intervention_name": "WoundWand\u2122 Debridement Device", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Standard of Care sharp debridement", 
                "description": "Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound", 
                "intervention_name": "Standard of Care sharp debridement", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "debridement", 
            "post-debridement", 
            "infection", 
            "prevention", 
            "wound", 
            "wound tissue", 
            "wound management", 
            "WoundWand", 
            "wound size reduction", 
            "wound bed debridement", 
            "WoundWand Debridement Device", 
            "chronic wound", 
            "delayed healing", 
            "cellular senescence", 
            "acute wound", 
            "diabetic foot ulcer", 
            "venous leg ulcers", 
            "radiofrequency debridement", 
            "necrotic tissue", 
            "wound healing", 
            "skin"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France"
                    }, 
                    "name": "Hopital Lapeyronie"
                }, 
                "investigator": {
                    "last_name": "Luc Teot, M.D., Phd.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "stephanie.yau@cmft.nhs.uk", 
                    "last_name": "Stephanie Yau", 
                    "phone": "0161-701-0168"
                }, 
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M13 0JE"
                    }, 
                    "name": "Manchester Diabetes Centre"
                }, 
                "investigator": {
                    "last_name": "Frank Bowling, Ph.D, FFPM, RCPS", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study of the WoundWand\u2122 Debridement Device on Infection Prevention", 
        "overall_official": {
            "affiliation": "Hopital Lapeyronie", 
            "last_name": "Luc Teot, M.D. Phd.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is to determine the bacterial diversity and number of bacteria present in the study wound at 4 weeks post- debridement using either WoundWand Debridement Device or Standard of Care", 
            "measure": "bacterial diversity and number of bacteria", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01924806"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "a)\tReduction in wound size for up to 12 weeks post-debridement", 
                "measure": "Reduction in wound size", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "b)\tHealth Economic data relating to the surgery (i.e., operating room time, surgical time), length of stay, admission, discharge, return to normal activities, medications, investigation site visits, and other related intervention and procedural costs and billing information may be collected when available", 
                "measure": "Health economic data", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "c)\tIncidence of complete wound closure within 12 weeks post-debridement", 
                "measure": "Wound closure", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "ArthroCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ArthroCare Corporation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}